(3R)-4-[4-(4-chlorophenoxy)-3-fluorophenyl]sulfonyl-1-N-ethyl-3-N-hydroxy-1-N-(2-hydroxyethyl)piperazine-1,3-dicarboxamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (3R)-4-[4-(4-chlorophenoxy)-3-fluorophenyl]sulfonyl-1-N-ethyl-3-N-hydroxy-1-N-(2-hydroxyethyl)piperazine-1,3-dicarboxamide
• 化学式: C₂₂H₂₆ClFN₄O₇S
• 分子量: 545.0
• InChiKey: VWANNTQGKJXOSJ-LJQANCHMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  36
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  148
• 氢给体数：
  3
• 氢受体数：
  9

文献信息

• [EN] SELECTIVE MMP INHIBITORS<br/>[FR] INHIBITEURS SÉLECTIFS DE MMP
  申请人：SYMPHONY EVOLUTION INC

  公开号：WO2014028334A1

  公开（公告）日：2014-02-20

  Described are methods for treating diseases by use of agents that selectively inhibit human metalloproteinases (MMP), such as MMP-9 and MMP-2, while optionally sparing MMP-1. Prevention of atherosclerotic plaque development and rupture and/or carotid arterial plaque development and rupture, by MMP inhibition can reduce the adverse consequences of plaque development and rupture including thromboembolism, stroke, myocardial infarction and acute coronary syndromes.